Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 16/20 | 1.00 |
| ▸ | KDM5A | P29375 | 14/20 | 1.00 |
| ▸ | PHF8 | Q9UPP1 | 5/20 | 1.00 |
| ▸ | KDM5C | P41229 | 1/20 | 0.97 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.97 |
| ▸ | KDM4A | O75164 | 7/20 | 0.94 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.71 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9834650 | 0.86 | KDM4C (0.76) | KDM4CKDM5APHF8KDM5CKDM5B | |
| SCHEMBL11587594 | 0.84 | KDM4C (0.72) | KDM4CKDM5APHF8KDM5CKDM5B | |
| SCHEMBL8359768 | 0.84 | KDM4C (0.72) | KDM4CKDM5APHF8KDM5CKDM5B | |
| SCHEMBL8341418 | 0.84 | KDM4C (0.72) | KDM4CKDM5APHF8KDM5CKDM5B | |
| SCHEMBL6751342 | 0.84 | KDM4C (0.72) | KDM4CKDM5APHF8KDM5CKDM5B | |
| Stearic Acid SCHEMBL5371023 | 0.84 | KDM4C (0.72) | KDM4CKDM5APHF8KDM5CKDM5B | |
| SCHEMBL10988412 | 0.84 | KDM4C (0.72) | KDM4CKDM5APHF8KDM5CKDM5B | |
| Octanoic Acid SCHEMBL9782585 | 0.84 | KDM4C (0.72) | KDM4CKDM5APHF8KDM5CKDM5B | |
| SCHEMBL5984578 | 0.84 | KDM4C (0.72) | KDM4CKDM5APHF8KDM5CKDM5B | |
| SCHEMBL4174660 | 0.84 | KDM4C (0.72) | KDM4CKDM5APHF8KDM5CKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240139197-A1 | INHIBITION OF KDM5A FOR PROMOTING ANTIGEN PRESENTATION, INCREASING CD8+ T CELL INFILTRATION AND BOOSTING ANTI-TUMOR IMMUNE RESPONSE | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY | 2024-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139197-A1 | INHIBITION OF KDM5A FOR PROMOTING ANTIGEN PRESENTATION, INCREASING CD8+ T CELL INFILTRATION AND BOOSTING ANTI-TUMOR IMMUNE RESPONSE | KDM5A, KDM5B, KDM5C | KDM4C 22/4885KDM5A 1/4885PHF8 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.